PRGO

#4422
Perrigo Company plc Ordinary Shares
0.1 1 USD
-3.57%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
0.11
0.11
年范围
0.11
22.01
日变化
-3.57%
每月变动
-99.02%
6个月变化
-99.17%
年变化
-99.49%
前一天收盘价
0.1 1
Open
0.1 1
最低价
0.1 1
High
0.1 1
交易量
1 167
展开完整图表 完整图表

Financials

概览 声明 统计 股息
每季度 年度
  • Market Capitalization 15.3 M
  • Employee 8 100
  • Founded N/A
  • CEO Murray S. Kessler
  • Website www.perrigo.com
  • Headquarter Ireland
  • FIGI N/A
  • Industry 药品制造—专业与仿制药
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
-0.74
市销率
0.32
每股股息
0.29
股息收益率 %
20.88

Perrigo Company plc Ordinary Shares

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park. Perrigo engages in the acquisition, manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients, primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value.

新闻